

Lars-Gunnar Larsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/916134/publications.pdf>

Version: 2024-02-01

45
papers

5,268
citations

257101

24
h-index

243296

44
g-index

48
all docs

48
docs citations

48
times ranked

10344
citing authors

#	ARTICLE	IF	CITATIONS
1	Direct observation of individual endogenous protein complexes in situ by proximity ligation. <i>Nature Methods</i> , 2006, 3, 995-1000.	9.0	2,103
2	The F-Box Protein Skp2 Participates in c-Myc Proteasomal Degradation and Acts as a Cofactor for c-Myc-Regulated Transcription. <i>Molecular Cell</i> , 2003, 11, 1189-1200.	4.5	441
3	c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. <i>Nature Cell Biology</i> , 2005, 7, 303-310.	4.6	421
4	Myc represses differentiation-induced p21 ^{CIP1} expression via Miz-1-dependent interaction with the p21 core promoter. <i>Oncogene</i> , 2003, 22, 351-360.	2.6	277
5	c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. <i>Blood</i> , 2000, 95, 2104-2110.	0.6	244
6	The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E187-96.	3.3	226
7	Cdk2 suppresses cellular senescence induced by the c-myc oncogene. <i>Nature Cell Biology</i> , 2010, 12, 54-59.	4.6	218
8	The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: Function and regulation. <i>Oncogene</i> , 1999, 18, 2955-2966.	2.6	179
9	Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 58-63.	3.3	167
10	Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence. <i>Seminars in Cancer Biology</i> , 2011, 21, 367-376.	4.3	119
11	The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy. <i>Experimental Cell Research</i> , 2010, 316, 1429-1437.	1.2	89
12	A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation. <i>Scientific Reports</i> , 2018, 8, 10064.	1.6	85
13	CDK-mediated activation of the SCF ^{FBXO} ubiquitin ligase promotes MYC-driven transcription and tumorigenesis and predicts poor survival in breast cancer. <i>EMBO Molecular Medicine</i> , 2013, 5, 1067-1086.	3.3	61
14	Myc Is Required for Activation of the ATM-Dependent Checkpoints in Response to DNA Damage. <i>PLoS ONE</i> , 2010, 5, e8924.	1.1	59
15	MYC Modulation around the CDK2/p27/SKP2 Axis. <i>Genes</i> , 2017, 8, 174.	1.0	58
16	Cdk2: a key regulator of the senescence control function of Myc. <i>Aging</i> , 2010, 2, 244-250.	1.4	47
17	Analysis of the DNA-binding activities of Myc/Max/Mad network complexes during induced differentiation of U-937 monoblasts and F9 teratocarcinoma cells. <i>Oncogene</i> , 1997, 15, 737-748.	2.6	38
18	The Role of Bcl-2 in the Pathogenesis of B Chronic Lymphocytic Leukemia. <i>Leukemia and Lymphoma</i> , 1993, 11, 173-179.	0.6	35

#	ARTICLE	IF	CITATIONS
19	Tipping the Balance: Cdk2 Enables Myc to Suppress Senescence. <i>Cancer Research</i> , 2010, 70, 6687-6691.	0.4	33
20	Targeting MYC Translation in Colorectal Cancer. <i>Cancer Discovery</i> , 2015, 5, 701-703.	7.7	30
21	Sin3b Interacts with Myc and Decreases Myc Levels. <i>Journal of Biological Chemistry</i> , 2014, 289, 22221-22236.	1.6	29
22	Implication of the ubiquitin/proteasome system in Myc-regulated transcription. <i>Cell Cycle</i> , 2003, 2, 403-7.	1.3	28
23	Posttranslational Regulation of Myc Function in Response to Phorbol Ester/Interferon- β -Induced Differentiation of v-Myc-Transformed U-937 Monoblasts. <i>Blood</i> , 1999, 93, 3900-3912.	0.6	27
24	Interferon- γ cooperates with retinoic acid and phorbol ester to induce differentiation and growth inhibition of human neuroblastoma cells. <i>International Journal of Cancer</i> , 2001, 94, 97-108.	2.3	26
25	TGF- β 2 enforces senescence in Myc-transformed hematopoietic tumor cells through induction of Mad1 and repression of Myc activity. <i>Experimental Cell Research</i> , 2009, 315, 3099-3111.	1.2	26
26	Combined IFN- β and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2634-2641.	1.9	25
27	Drug-induced Myc-mediated apoptosis of cancer cells is inhibited by stress protein Hsp70. <i>International Journal of Cancer</i> , 2007, 121, 2615-2621.	2.3	24
28	Inhibition of the Intrinsic but Not the Extrinsic Apoptosis Pathway Accelerates and Drives Myc-Driven Tumorigenesis Towards Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2012, 7, e31366.	1.1	21
29	MYC Synergizes with Activated BRAFV600E in Mouse Lung Tumor Development by Suppressing Senescence. <i>Cancer Research</i> , 2014, 74, 4222-4229.	0.4	15
30	PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer. <i>ELife</i> , 2020, 9, .	2.8	15
31	Characterization of A U-937 subline which can be induced to differentiate in serum-free medium. <i>International Journal of Cancer</i> , 1992, 50, 153-160.	2.3	13
32	MYC and RAS are unable to cooperate in overcoming cellular senescence and apoptosis in normal human fibroblasts. <i>Cell Cycle</i> , 2018, 17, 2697-2715.	1.3	13
33	Interferon- β -induced p27KIP1 binds to and targets MYC for proteasome-mediated degradation. <i>Oncotarget</i> , 2016, 7, 2837-2854.	0.8	12
34	The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cells. <i>Investigational New Drugs</i> , 2021, 39, 587-594.	1.2	10
35	MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding. <i>Cancer Research Communications</i> , 2022, 2, 110-130.	0.7	10
36	SNIP1: Myc's New Helper in Transcriptional Activation. <i>Molecular Cell</i> , 2006, 24, 811-812.	4.5	7

#	ARTICLE	IF	CITATIONS
37	Pharmacological inactivation of CDK2 inhibits MYC/BCL-XL-driven leukemia in vivo through induction of cellular senescence. <i>Cell Cycle</i> , 2021, 20, 23-38.	1.3	7
38	Mad 1 Inhibits Cell Growth and Proliferation but Does Not Promote Differentiation or Overall Survival in Human U-937 Monoblasts. <i>Molecular Cancer Research</i> , 2004, 2, 464-476.	1.5	7
39	MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner. <i>Cancer Research Communications</i> , 2022, 2, 182-201.	0.7	6
40	Cellular senescence – A barrier against tumor development?. <i>Seminars in Cancer Biology</i> , 2011, 21, 347-348.	4.3	5
41	C-Jun is Induced to High Continuous Expression During Differentiation of Hematopoietic Cells and is Regulated Independently from C-Fos. <i>Leukemia and Lymphoma</i> , 1991, 4, 193-204.	0.6	4
42	Methods to Study Myc-Regulated Cellular Senescence: An Update. <i>Methods in Molecular Biology</i> , 2021, 2318, 241-254.	0.4	3
43	Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	1.6	3
44	Methods to Study MYC-Regulated Cellular Senescence. <i>Methods in Molecular Biology</i> , 2013, 1012, 99-116.	0.4	2
45	Novel Allosteric Mechanism of P53 Activation by Small Molecules for Targeted Anticancer Therapy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0